Adaptimmune Therapeutics plc American (ADAP) Free Cash Flow by Year
Adaptimmune Therapeutics plc American recorded an outflow of $74.1M in free cash flow in fiscal year 2024. This represents an increase of 49.1% from the prior fiscal year. Over the trailing 12 months, Q3 FY2024 through Q2 FY2025, the same line adds up to an outflow of $191.7M in free cash flow. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters Adaptimmune Therapeutics plc American has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ADAP Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -$191.7M | -$74.1M+49.1% | -$145.6M+15.0% | -$171.3M-8047.3% | $2.2M+103.9% | -$55.9M+51.0% | -$114.1M-5.4% | -$108.3M-37.2% | -$79.0M-32.3% | -$59.7M-71.7% | -$34.7M-198.0% | $35.5M+427.2% | -$10.8M |
TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.
ADAP Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Adaptimmune Therapeutics plc American financials
Frequently Asked Questions
What was Adaptimmune Therapeutics plc American's free cash flow in fiscal year 2024?
Adaptimmune Therapeutics plc American recorded an outflow of $74.1M in free cash flow in fiscal year 2024.
How fast is Adaptimmune Therapeutics plc American's free cash flow growing?
Adaptimmune Therapeutics plc American (ADAP) free cash flow rose by 49.1% year over year, from -$145.6M to -$74.1M in fiscal year 2024.
What is Adaptimmune Therapeutics plc American's free cash flow over the last twelve months?
Adaptimmune Therapeutics plc American (ADAP) reported an outflow of $191.7M in free cash flow over the trailing 12 months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.
How has Adaptimmune Therapeutics plc American's free cash flow changed over the years?
Across the 12 fiscal years this page covers, Adaptimmune Therapeutics plc American (ADAP) free cash flow went from -$10.8M in fiscal year 2013 to -$74.1M in fiscal year 2024.
What was Adaptimmune Therapeutics plc American's free cash flow in the most recent quarter?
Adaptimmune Therapeutics plc American (ADAP) reported -$34.9M in free cash flow in Q2 2025. This represents a decrease of 174.2% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Adaptimmune Therapeutics plc American (ADAP) reported on that line in every period on record.